Evidence map›Paper›PMID 37612771›Full record

ArticleAllergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology2023

Anxiety in adults with asthma during the coronavirus disease 2019 pandemic: a Canadian perspective.

Sophia Linton, Kayley Xu, Lubnaa Hossenbaccus, Hannah Botting, Sarah Garvey, Adam Sunavsky, Lisa M Steacy, Dean A Tripp, Anne K Ellis

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Sophia LintonDepartment of Medicine, Queen's University, Kingston, ON, Canada.
Kayley XuDepartment of Medicine, Queen's University, Kingston, ON, Canada.
Lubnaa HossenbaccusDepartment of Medicine, Queen's University, Kingston, ON, Canada.
Hannah BottingKingston General Health Research Institute-Allergy Research Unit, Kingston, ON, Canada.
Sarah GarveyKingston General Health Research Institute-Allergy Research Unit, Kingston, ON, Canada.
Adam SunavskyDepartment of Medicine, University of British Columbia, Vancouver, BC, Canada.
Lisa M SteacyKingston General Health Research Institute-Allergy Research Unit, Kingston, ON, Canada.
Dean A TrippDepartment of Medicine, Queen's University, Kingston, ON, Canada.
Anne K EllisDepartment of Medicine, Queen's University, Kingston, ON, Canada. Anne.Ellis@kingstonhsc.ca.
Kingston Health Sciences Centre · CAQueen's University · CAUniversity of British Columbia · CA

Funding

AstraZeneca ESR-20-20714Kingston Allergy Research Kingston Allergy ResearchMedexus MedexusMiravo MiravoReve Pharma Reve Pharma
6 · The paper itself

Abstract

backgroundAsthma is a chronic airway inflammatory disease that affects millions of Canadians and often contributes to higher levels of anxiety among patients. Since the coronavirus disease 2019 (COVID-19) pandemic was a time of increased anxiety and fear among the Canadian population, it was thought that those with asthma may experience heightened anxiety levels due to uncertain access to care, the potential to misinterpret asthma symptoms for symptoms of COVID-19 (or vice versa), and the concern about being treated differently by those around them when experiencing asthma symptoms. Therefore, this study sought to perform a cross-sectional analysis of the asthma-anxiety relationship in adults with and without asthma in the unique context of the COVID-19 pandemic from a Canadian perspective.

methodsThis study employed the COVID-19 Associated Anxiety in Allergic Rhinitis and Asthma patients Experiencing Symptoms (CAAARES) survey, consisting of COVID-19-specific questions, the Generalized Anxiety Disorder Assessment-7 (GAD-7) and the Asthma Control Questionnaire-6 (ACQ-6). Data collection occurred through the Qualtrics XM platform and data analyses were conducted with the IBM SPSS Statistics 28 software.

resultsA total of 741 valid responses were collected (asthma group, n = 244; control group, n = 497). 31.6% and 26.2% of respondents in the asthma and control groups, respectively, met the diagnostic criteria for GAD. There was no significant difference (p = .067) in mean GAD-7 scores between the two groups. A Hierarchal Multiple Regression (HMR) model was developed, and neither asthma status nor ACQ-6 score had a significant predictive effect on the GAD-7 score. There was a statistically significant (p < .001) weak positive correlation (r = .22) between GAD-7 and ACQ-6 scores. In a simple mediation (SMM) model, perceived COVID-19 stress of others was not identified as a significant mediator of the relationship between ACQ-6 and GAD-7 (indirect effect β = 0.014).

conclusionOur study of a Canadian cohort demonstrates elevated levels of anxiety overall, amongst both asthma and control groups. While AR status was significantly greater in the asthma group, it was not a significant predictive variable of GAD-7 score. Our data suggests that COVID-19-specific factors appear to have a greater contribution to anxiety than asthma status or control.

Indexed as

AllergiesAnxietyAsthmaCOVID-19

Identifiers

PMID37612771
PMCPMC10463471
OpenAlexW4386096545

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.